Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 216

1.

Treatment with 5-azacitidine delay growth of glioblastoma xenografts: a potential new treatment approach for glioblastomas.

Kratzsch T, Kuhn SA, Joedicke A, Hanisch UK, Vajkoczy P, Hoffmann J, Fichtner I.

J Cancer Res Clin Oncol. 2018 Feb 9. doi: 10.1007/s00432-018-2600-1. [Epub ahead of print]

PMID:
29427211
2.

Loss-of-function uORF mutations in human malignancies.

Schulz J, Mah N, Neuenschwander M, Kischka T, Ratei R, Schlag PM, Castaños-Vélez E, Fichtner I, Tunn PU, Denkert C, Klaas O, Berdel WE, von Kries JP, Makalowski W, Andrade-Navarro MA, Leutz A, Wethmar K.

Sci Rep. 2018 Feb 5;8(1):2395. doi: 10.1038/s41598-018-19201-8.

3.

Acquired Resistance of ER-Positive Breast Cancer to Endocrine Treatment Confers an Adaptive Sensitivity to TRAIL through Posttranslational Downregulation of c-FLIP.

Piggott L, Silva A, Robinson T, Santiago-Gómez A, Simões BM, Becker M, Fichtner I, Andera L, Young P, Morris C, Barrett-Lee P, Alchami F, Piva M, Vivanco MD, Clarke RB, Gee J, Clarkson R.

Clin Cancer Res. 2018 Jan 23. doi: 10.1158/1078-0432.CCR-17-1381. [Epub ahead of print]

PMID:
29363524
4.

Animal models for personalized treatment options.

Fichtner I, Klinghammer K, Behrens D, Flechsig S, Rolff J, Becker M, Wulf-Goldenberg A, Stecklum M, Rivera M, Brzezicha B, Jandrig B, Hoffmann J.

Int J Clin Pharmacol Ther. 2017 Aug;55(8):698-700. doi: 10.5414/CPXCES15EA09. No abstract available.

PMID:
28696202
5.

Pharmacologically directed strategies in academic anticancer drug discovery based on the European NCI compounds initiative.

Hendriks HR, Govaerts AS, Fichtner I, Burtles S, Westwell AD, Peters GJ.

Br J Cancer. 2017 Jul 11;117(2):195-202. doi: 10.1038/bjc.2017.167. Epub 2017 Jun 13.

PMID:
28609434
6.

Basal subtype is predictive for response to cetuximab treatment in patient-derived xenografts of squamous cell head and neck cancer.

Klinghammer K, Otto R, Raguse JD, Albers AE, Tinhofer I, Fichtner I, Leser U, Keilholz U, Hoffmann J.

Int J Cancer. 2017 Sep 15;141(6):1215-1221. doi: 10.1002/ijc.30808. Epub 2017 Jun 21.

PMID:
28560858
7.

Pancreatic cancer models for translational research.

Behrens D, Walther W, Fichtner I.

Pharmacol Ther. 2017 May;173:146-158. doi: 10.1016/j.pharmthera.2017.02.013. Epub 2017 Feb 4. Review. No abstract available.

PMID:
28174092
8.

QSEA-modelling of genome-wide DNA methylation from sequencing enrichment experiments.

Lienhard M, Grasse S, Rolff J, Frese S, Schirmer U, Becker M, Börno S, Timmermann B, Chavez L, Sültmann H, Leschber G, Fichtner I, Schweiger MR, Herwig R.

Nucleic Acids Res. 2017 Apr 7;45(6):e44. doi: 10.1093/nar/gkw1193.

9.

Pharmacologic activity and pharmacokinetics of metabolites of regorafenib in preclinical models.

Zopf D, Fichtner I, Bhargava A, Steinke W, Thierauch KH, Diefenbach K, Wilhelm S, Hafner FT, Gerisch M.

Cancer Med. 2016 Nov;5(11):3176-3185. doi: 10.1002/cam4.883. Epub 2016 Oct 13.

10.

Improved Treatment of MT-3 Breast Cancer and Brain Metastases in a Mouse Xenograft by LRP-Targeted Oxaliplatin Liposomes.

Orthmann A, Peiker L, Fichtner I, Hoffmann A, Hilger RA, Zeisig R.

J Biomed Nanotechnol. 2016 Jan;12(1):56-68.

PMID:
27301172
11.

Preclinical Study of a Combination of Erlotinib and Bevacizumab in Early Stages of Unselected Non-Small Cell Lung Cancer Patient-Derived Xenografts.

Rolff J, Becker M, Merk J, Hoffmann J, Fichtner I.

Target Oncol. 2016 Aug;11(4):507-14. doi: 10.1007/s11523-015-0415-4.

PMID:
26817645
12.

SPON2, a newly identified target gene of MACC1, drives colorectal cancer metastasis in mice and is prognostic for colorectal cancer patient survival.

Schmid F, Wang Q, Huska MR, Andrade-Navarro MA, Lemm M, Fichtner I, Dahlmann M, Kobelt D, Walther W, Smith J, Schlag PM, Stein U.

Oncogene. 2016 Nov 17;35(46):5942-5952. doi: 10.1038/onc.2015.451. Epub 2015 Dec 21.

PMID:
26686083
13.

Investigation of cell culture volatilomes using solid phase micro extraction: Options and pitfalls exemplified with adenocarcinoma cell lines.

Schallschmidt K, Becker R, Jung C, Rolff J, Fichtner I, Nehls I.

J Chromatogr B Analyt Technol Biomed Life Sci. 2015 Dec 1;1006:158-166. doi: 10.1016/j.jchromb.2015.10.004. Epub 2015 Oct 20.

PMID:
26551208
14.

New Wnt/β-catenin target genes promote experimental metastasis and migration of colorectal cancer cells through different signals.

Qi J, Yu Y, Akilli Öztürk Ö, Holland JD, Besser D, Fritzmann J, Wulf-Goldenberg A, Eckert K, Fichtner I, Birchmeier W.

Gut. 2016 Oct;65(10):1690-701. doi: 10.1136/gutjnl-2014-307900. Epub 2015 Jul 8.

PMID:
26156959
15.

Histone acetyltransferase inhibitors block neuroblastoma cell growth in vivo.

Gajer JM, Furdas SD, Gründer A, Gothwal M, Heinicke U, Keller K, Colland F, Fulda S, Pahl HL, Fichtner I, Sippl W, Jung M.

Oncogenesis. 2015 Feb 9;4:e137. doi: 10.1038/oncsis.2014.51.

16.

A comprehensively characterized large panel of head and neck cancer patient-derived xenografts identifies the mTOR inhibitor everolimus as potential new treatment option.

Klinghammer K, Raguse JD, Plath T, Albers AE, Joehrens K, Zakarneh A, Brzezicha B, Wulf-Goldenberg A, Keilholz U, Hoffmann J, Fichtner I.

Int J Cancer. 2015 Jun 15;136(12):2940-8. doi: 10.1002/ijc.29344. Epub 2014 Nov 26.

17.

Essential role of IRF4 and MYC signaling for survival of anaplastic large cell lymphoma.

Weilemann A, Grau M, Erdmann T, Merkel O, Sobhiafshar U, Anagnostopoulos I, Hummel M, Siegert A, Hayford C, Madle H, Wollert-Wulf B, Fichtner I, Dörken B, Dirnhofer S, Mathas S, Janz M, Emre NC, Rosenwald A, Ott G, Lenz P, Tzankov A, Lenz G.

Blood. 2015 Jan 1;125(1):124-32. doi: 10.1182/blood-2014-08-594507. Epub 2014 Oct 30.

18.

Cell differentiation mediated by co-culture of human umbilical cord blood stem cells with murine hepatic cells.

Stecklum M, Wulf-Goldenberg A, Purfürst B, Siegert A, Keil M, Eckert K, Fichtner I.

In Vitro Cell Dev Biol Anim. 2015 Feb;51(2):183-91. doi: 10.1007/s11626-014-9817-3. Epub 2014 Oct 1.

PMID:
25270685
19.

Activation of AMP-activated protein kinase sensitizes lung cancer cells and H1299 xenografts to erlotinib.

Hülsmann HJ, Rolff J, Bender C, Jarahian M, Korf U, Herwig R, Fröhlich H, Thomas M, Merk J, Fichtner I, Sültmann H, Kuner R.

Lung Cancer. 2014 Nov;86(2):151-7. doi: 10.1016/j.lungcan.2014.09.001. Epub 2014 Sep 10.

PMID:
25240516
20.

Antitumor efficacy, pharmacokinetic and biodistribution studies of the anticancer peptide CIGB-552 in mouse models.

Vallespí MG, Pimentel G, Cabrales-Rico A, Garza J, Oliva B, Mendoza O, Gomez Y, Basaco T, Sánchez I, Calderón C, Rodriguez JC, Markelova MR, Fichtner I, Astrada S, Bollati-Fogolín M, Garay HE, Reyes O.

J Pept Sci. 2014 Nov;20(11):850-9. doi: 10.1002/psc.2676. Epub 2014 Jul 20.

PMID:
25044757
21.

Smac mimetic and glucocorticoids synergize to induce apoptosis in childhood ALL by promoting ripoptosome assembly.

Belz K, Schoeneberger H, Wehner S, Weigert A, Bönig H, Klingebiel T, Fichtner I, Fulda S.

Blood. 2014 Jul 10;124(2):240-50. doi: 10.1182/blood-2013-05-500918. Epub 2014 May 22.

22.

The nerve growth factor receptor CD271 is crucial to maintain tumorigenicity and stem-like properties of melanoma cells.

Redmer T, Welte Y, Behrens D, Fichtner I, Przybilla D, Wruck W, Yaspo ML, Lehrach H, Schäfer R, Regenbrecht CR.

PLoS One. 2014 May 5;9(5):e92596. doi: 10.1371/journal.pone.0092596. eCollection 2014. Erratum in: PLoS One. 2014;9(8):e105274.

23.

Opioid receptor activation triggering downregulation of cAMP improves effectiveness of anti-cancer drugs in treatment of glioblastoma.

Friesen C, Hormann I, Roscher M, Fichtner I, Alt A, Hilger R, Debatin KM, Miltner E.

Cell Cycle. 2014;13(10):1560-70. doi: 10.4161/cc.28493. Epub 2014 Mar 12.

24.

Preclinical study on combined chemo- and nonviral gene therapy for sensitization of melanoma using a human TNF-alpha expressing MIDGE DNA vector.

Kobelt D, Aumann J, Schmidt M, Wittig B, Fichtner I, Behrens D, Lemm M, Freundt G, Schlag PM, Walther W.

Mol Oncol. 2014 May;8(3):609-19. doi: 10.1016/j.molonc.2013.12.019. Epub 2014 Jan 18.

25.

Testing of SNS-032 in a Panel of Human Neuroblastoma Cell Lines with Acquired Resistance to a Broad Range of Drugs.

Löschmann N, Michaelis M, Rothweiler F, Zehner R, Cinatl J, Voges Y, Sharifi M, Riecken K, Meyer J, von Deimling A, Fichtner I, Ghafourian T, Westermann F, Cinatl J Jr.

Transl Oncol. 2013 Dec 1;6(6):685-96. eCollection 2013 Dec 1.

26.

A seven-year storage report of good manufacturing practice-grade naked plasmid DNA: stability, topology, and in vitro/in vivo functional analysis.

Walther W, Schmeer M, Kobelt D, Baier R, Harder A, Walhorn V, Anselmetti D, Aumann J, Fichtner I, Schleef M.

Hum Gene Ther Clin Dev. 2013 Dec;24(4):147-53. doi: 10.1089/humc.2013.067. Epub 2013 Oct 24.

PMID:
24067054
27.

Bi-PROF: bisulfite profiling of target regions using 454 GS FLX Titanium technology.

Gries J, Schumacher D, Arand J, Lutsik P, Markelova MR, Fichtner I, Walter J, Sers C, Tierling S.

Epigenetics. 2013 Jul;8(7):765-71. doi: 10.4161/epi.25242. Epub 2013 Jun 10.

28.

Cell death sensitization of leukemia cells by opioid receptor activation.

Friesen C, Roscher M, Hormann I, Fichtner I, Alt A, Hilger RA, Debatin KM, Miltner E.

Oncotarget. 2013 May;4(5):677-90.

29.

Synergistic activity of bortezomib and HDACi in preclinical models of B-cell precursor acute lymphoblastic leukemia via modulation of p53, PI3K/AKT, and NF-κB.

Bastian L, Hof J, Pfau M, Fichtner I, Eckert C, Henze G, Prada J, von Stackelberg A, Seeger K, Shalapour S.

Clin Cancer Res. 2013 Mar 15;19(6):1445-57. doi: 10.1158/1078-0432.CCR-12-1511. Epub 2013 Jan 28.

30.

Evaluation of combination therapy schedules of doxorubicin and an acid-sensitive albumin-binding prodrug of doxorubicin in the MIA PaCa-2 pancreatic xenograft model.

Kratz F, Azab S, Zeisig R, Fichtner I, Warnecke A.

Int J Pharm. 2013 Jan 30;441(1-2):499-506. doi: 10.1016/j.ijpharm.2012.11.003. Epub 2012 Nov 10.

PMID:
23149257
31.

Systemic shRNA mediated knock down of S100A4 in colorectal cancer xenografted mice reduces metastasis formation.

Dahlmann M, Sack U, Herrmann P, Lemm M, Fichtner I, Schlag PM, Stein U.

Oncotarget. 2012 Aug;3(8):783-97.

32.

Treatment of experimental brain metastasis with MTO-liposomes: impact of fluidity and LRP-targeting on the therapeutic result.

Orthmann A, Zeisig R, Süss R, Lorenz D, Lemm M, Fichtner I.

Pharm Res. 2012 Jul;29(7):1949-59. doi: 10.1007/s11095-012-0723-7. Epub 2012 Mar 8.

PMID:
22399388
33.

Transcriptional expression profile of cultured human embryonic stem cells in vitro and in vivo.

Keil M, Siegert A, Eckert K, Gerlach J, Haider W, Fichtner I.

In Vitro Cell Dev Biol Anim. 2012 Mar;48(3):165-74. doi: 10.1007/s11626-012-9487-y. Epub 2012 Feb 4.

PMID:
22311374
34.

Intrahepatic transplantation of CD34+ cord blood stem cells into newborn and adult NOD/SCID mice induce differential organ engraftment.

Wulf-Goldenberg A, Keil M, Fichtner I, Eckert K.

Tissue Cell. 2012 Apr;44(2):80-6. doi: 10.1016/j.tice.2011.11.004. Epub 2011 Dec 23.

PMID:
22197619
35.

Improving the transport of chemotherapeutic drugs across the blood-brain barrier.

Orthmann A, Fichtner I, Zeisig R.

Expert Rev Clin Pharmacol. 2011 Jul;4(4):477-90. doi: 10.1586/ecp.11.26. Review.

PMID:
22114857
36.

Novel Clostridium perfringens enterotoxin suicide gene therapy for selective treatment of claudin-3- and -4-overexpressing tumors.

Walther W, Petkov S, Kuvardina ON, Aumann J, Kobelt D, Fichtner I, Lemm M, Piontek J, Blasig IE, Stein U, Schlag PM.

Gene Ther. 2012 May;19(5):494-503. doi: 10.1038/gt.2011.136. Epub 2011 Oct 6.

PMID:
21975465
37.

Comparative evaluation of the biological properties of reducible and acid-sensitive folate prodrugs of a highly potent doxorubicin derivative.

Abu Ajaj K, El-Abadla N, Welker P, Azab S, Zeisig R, Fichtner I, Kratz F.

Eur J Cancer. 2012 Sep;48(13):2054-65. doi: 10.1016/j.ejca.2011.08.003. Epub 2011 Sep 19.

PMID:
21937219
38.

High prevalence and breast cancer predisposing role of the BLM c.1642 C>T (Q548X) mutation in Russia.

Sokolenko AP, Iyevleva AG, Preobrazhenskaya EV, Mitiushkina NV, Abysheva SN, Suspitsin EN, Kuligina ESh, Gorodnova TV, Pfeifer W, Togo AV, Turkevich EA, Ivantsov AO, Voskresenskiy DV, Dolmatov GD, Bit-Sava EM, Matsko DE, Semiglazov VF, Fichtner I, Larionov AA, Kuznetsov SG, Antoniou AC, Imyanitov EN.

Int J Cancer. 2012 Jun 15;130(12):2867-73. doi: 10.1002/ijc.26342. Epub 2011 Oct 20.

39.

S100A4-induced cell motility and metastasis is restricted by the Wnt/β-catenin pathway inhibitor calcimycin in colon cancer cells.

Sack U, Walther W, Scudiero D, Selby M, Aumann J, Lemos C, Fichtner I, Schlag PM, Shoemaker RH, Stein U.

Mol Biol Cell. 2011 Sep;22(18):3344-54. doi: 10.1091/mbc.E10-09-0739. Epub 2011 Jul 27.

40.

Novel effect of antihelminthic Niclosamide on S100A4-mediated metastatic progression in colon cancer.

Sack U, Walther W, Scudiero D, Selby M, Kobelt D, Lemm M, Fichtner I, Schlag PM, Shoemaker RH, Stein U.

J Natl Cancer Inst. 2011 Jul 6;103(13):1018-36. doi: 10.1093/jnci/djr190. Epub 2011 Jun 17.

PMID:
21685359
41.

Screening of well-established drugs targeting cancer metabolism: reproducibility of the efficacy of a highly effective drug combination in mice.

Abolhassani M, Guais A, Sanders E, Campion F, Fichtner I, Bonte J, Baronzio G, Fiorentini G, Israël M, Schwartz L.

Invest New Drugs. 2012 Aug;30(4):1331-42. doi: 10.1007/s10637-011-9692-7. Epub 2011 Jun 9.

PMID:
21655919
42.

Development of resistance towards artesunate in MDA-MB-231 human breast cancer cells.

Bachmeier B, Fichtner I, Killian PH, Kronski E, Pfeffer U, Efferth T.

PLoS One. 2011;6(5):e20550. doi: 10.1371/journal.pone.0020550. Epub 2011 May 26.

43.

Combination therapy with the albumin-binding prodrug of doxorubicin (INNO-206) and doxorubicin achieves complete remissions and improves tolerability in an ovarian A2780 xenograft model.

Kratz F, Fichtner I, Graeser R.

Invest New Drugs. 2012 Aug;30(4):1743-9. doi: 10.1007/s10637-011-9686-5. Epub 2011 May 18. No abstract available.

PMID:
21590366
44.

Chemoresistance in non-small-cell lung cancer: can multidrug resistance markers predict the response of xenograft lung cancer models to chemotherapy?

Merk J, Rolff J, Dorn C, Leschber G, Fichtner I.

Eur J Cardiothorac Surg. 2011 Jul;40(1):e29-33. doi: 10.1016/j.ejcts.2011.02.010. Epub 2011 Mar 21.

PMID:
21420313
45.

Intervening in β-catenin signaling by sulindac inhibits S100A4-dependent colon cancer metastasis.

Stein U, Arlt F, Smith J, Sack U, Herrmann P, Walther W, Lemm M, Fichtner I, Shoemaker RH, Schlag PM.

Neoplasia. 2011 Feb;13(2):131-44.

46.

Low cytosine triphosphate synthase 2 expression renders resistance to 5-fluorouracil in colorectal cancer.

Tan WL, Bhattacharya B, Loh M, Balasubramanian I, Akram M, Dong D, Wong L, Thakkar B, Salto-Tellez M, Soo RA, Fichtner I, Iacopetta B, Soong R.

Cancer Biol Ther. 2011 Mar 15;11(6):599-608. Epub 2011 Mar 15.

PMID:
21378502
47.

Development of efficient acid cleavable multifunctional prodrugs derived from dendritic polyglycerol with a poly(ethylene glycol) shell.

Calderón M, Welker P, Licha K, Fichtner I, Graeser R, Haag R, Kratz F.

J Control Release. 2011 May 10;151(3):295-301. doi: 10.1016/j.jconrel.2011.01.017. Epub 2011 Jan 21.

PMID:
21256902
48.

Intrahepatically transplanted human cord blood cells reduce SW480 tumor growth in the presence of bispecific EpCAM/CD3 antibody.

Wulf-Goldenberg A, Eckert K, Fichtner I.

Cytotherapy. 2011 Jan;13(1):108-13. doi: 10.3109/14653249.2010.515577. Epub 2010 Sep 15.

PMID:
20839999
49.

Activation of the CMV-IE promoter by hyperthermia in vitro and in vivo: biphasic heat induction of cytosine deaminase suicide gene expression.

Kobelt D, Aumann J, Fichtner I, Stein U, Schlag PM, Walther W.

Mol Biotechnol. 2010 Oct;46(2):197-205. doi: 10.1007/s12033-010-9292-3.

PMID:
20512535
50.

Delivery of 5-azacytidine to human cancer cells by elaidic acid esterification increases therapeutic drug efficacy.

Brueckner B, Rius M, Markelova MR, Fichtner I, Hals PA, Sandvold ML, Lyko F.

Mol Cancer Ther. 2010 May;9(5):1256-64. doi: 10.1158/1535-7163.MCT-09-1202. Epub 2010 May 4.

Supplemental Content

Loading ...
Support Center